Mar 16, 2018 8:00am EDT OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology
Mar 01, 2018 4:05pm EST OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results
Feb 26, 2018 4:05pm EST OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018
Jan 12, 2018 8:00am EST OPKO’S GeneDx Announces Research Collaboration with Radboud University Medical Center
Nov 27, 2017 11:02am EST OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy
Nov 07, 2017 8:00am EST OPKO Health Submits Premarket Approval Application with FDA for a Point-of-Care PSA Test with the Claros® 1 Platform
Nov 03, 2017 9:43am EDT OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017
Oct 26, 2017 10:19am EDT OPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with Chemotherapy